Show simple item record

dc.contributor.authorFujimura, Takashi
dc.contributor.authorOhta, Tetsuo
dc.contributor.authorOyama, Katsunobu
dc.contributor.authorMiyashita, Tomoharu
dc.contributor.authorMiwa, Koichi
dc.date.accessioned2009-04-15T12:00:35Z
dc.date.available2009-04-15T12:00:35Z
dc.date.issued2006-03-07
dc.identifier.citationWorld J. Gastroenterol. 2006, 12 (9):1336-1345en
dc.identifier.issn1007-9327
dc.identifier.pmid16552798
dc.identifier.urihttp://hdl.handle.net/10146/64976
dc.descriptionKEYWORDS CLASSIFICATION: adverse effects;analysis;Adenomatous Polyposis Coli;chemically induced;chemistry;Cardiovascular Diseases;Cell Proliferation;Colorectal Neoplasms;Cyclooxygenase 2;Cyclooxygenase 2 Inhibitors;drug effects;drug therapy;Dinoprostone;etiology;Esophageal Neoplasms;Food;genetics;Gastrointestinal Neoplasms;Humans;Intestinal Mucosa;Japan;metabolism;mechanisms of carcinogenesis;pharmacology;physiology;physiopathology;prevention & control;Risk Factors;RNA,Messenger;Stomach Neoplasms;therapeutic use.en
dc.description.abstractSelective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However,coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP),which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum,and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors.
dc.language.isoenen
dc.relation.urlhttp://www.wjgnet.com/1007-9327/12/1336.aspen
dc.subjectCyclooxygenase-2 (COX-2)en
dc.subjectSelective COX-2 inhibitorsen
dc.subjectEsophageal canceren
dc.subjectGastric canceren
dc.subjectColorectal canceren
dc.subject.meshAdenomatous Polyposis Coli
dc.subject.meshCardiovascular Diseases
dc.subject.meshCell Proliferation
dc.subject.meshColorectal Neoplasms
dc.subject.meshCyclooxygenase 2
dc.subject.meshCyclooxygenase 2 Inhibitors
dc.subject.meshDinoprostone
dc.subject.meshEsophageal Neoplasms
dc.subject.meshGastrointestinal Neoplasms
dc.subject.meshHumans
dc.subject.meshIntestinal Mucosa
dc.subject.meshRNA, Messenger
dc.subject.meshRisk Factors
dc.subject.meshStomach Neoplasms
dc.titleRole of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience.en
dc.typeArticleen
dc.identifier.journalWorld journal of gastroenterology : WJGen
refterms.dateFOA2018-12-17T18:13:02Z
html.description.abstractSelective cyclooxygenase (COX)-2 inhibitors (coxibs) were developed as one of the anti-inflammatory drugs to avoid the various side effects of non-steroidal anti-inflammatory drugs (NSAIDs). However,coxibs also have an ability to inhibit tumor development of various kinds the same way that NSAIDs do. Many experimental studies using cell lines and animal models demonstrated an ability to prevent tumor proliferation of COX-2 inhibitors. After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP),which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S. Food and Drug Administration (FDA) immediately approved the clinical use of celecoxib for FAP patients. However, some coxibs were recently reported to increase the risk of serious cardiovascular events including heart attack and stroke. In this article we review a role of COX-2 in carcinogenesis of gastrointestinal tract, such as the esophagus, stomach and colorectum,and also analyze the prospect of coxibs for chemoprevention of gastrointestinal tract tumors.


Files in this item

Thumbnail
Name:
World J Gastroentrol 1336.pdf
Size:
475.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record